UBS Asset Management Americas Inc. trimmed its position in shares of Teligent, Inc. (NASDAQ:TLGT) by 41.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,803 shares of the company’s stock after selling 8,934 shares during the quarter. UBS Asset Management Americas Inc.’s holdings in Teligent were worth $117,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently bought and sold shares of TLGT. RK Capital Management LLC purchased a new position in shares of Teligent in the 2nd quarter worth about $4,581,000. Icon Advisers Inc. Co. purchased a new position in shares of Teligent in the 2nd quarter worth about $754,000. TIAA CREF Investment Management LLC boosted its holdings in shares of Teligent by 5.4% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 111,506 shares of the company’s stock worth $1,020,000 after buying an additional 5,691 shares during the last quarter. Teachers Advisors LLC boosted its holdings in shares of Teligent by 7.6% in the 2nd quarter. Teachers Advisors LLC now owns 74,109 shares of the company’s stock worth $678,000 after buying an additional 5,216 shares during the last quarter. Finally, Timpani Capital Management LLC purchased a new position in shares of Teligent in the 2nd quarter worth about $1,692,000. 66.44% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Teligent, Inc. (TLGT) opened at $2.96 on Wednesday. Teligent, Inc. has a 52-week low of $2.82 and a 52-week high of $9.54. The firm has a market capitalization of $165.52, a PE ratio of 172.33, a PEG ratio of 17.23 and a beta of 1.50. The company has a current ratio of 4.37, a quick ratio of 3.71 and a debt-to-equity ratio of 1.99.

Teligent (NASDAQ:TLGT) last announced its quarterly earnings results on Monday, November 6th. The company reported ($0.08) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.01) by ($0.07). Teligent had a negative net margin of 11.36% and a positive return on equity of 1.49%. The company had revenue of $13.65 million for the quarter, compared to the consensus estimate of $19.12 million. During the same quarter in the prior year, the company earned $0.01 earnings per share. The company’s quarterly revenue was down 15.5% on a year-over-year basis. sell-side analysts predict that Teligent, Inc. will post 0.02 EPS for the current year.

A number of equities analysts recently weighed in on TLGT shares. Deutsche Bank AG reissued a “hold” rating and issued a $9.00 price target (up from $8.00) on shares of Teligent in a report on Monday, July 17th. Canaccord Genuity initiated coverage on Teligent in a research note on Monday, July 31st. They issued a “buy” rating and a $11.00 price objective on the stock. BidaskClub cut Teligent from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 1st. Zacks Investment Research upgraded Teligent from a “strong sell” rating to a “hold” rating in a research note on Friday, October 13th. Finally, ValuEngine cut Teligent from a “hold” rating to a “sell” rating in a research note on Tuesday, July 25th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $7.33.

WARNING: “UBS Asset Management Americas Inc. Has $117,000 Holdings in Teligent, Inc. (TLGT)” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/11/08/ubs-asset-management-americas-inc-has-117000-holdings-in-teligent-inc-tlgt.html.

Teligent Profile

Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.

Institutional Ownership by Quarter for Teligent (NASDAQ:TLGT)

Receive News & Stock Ratings for Teligent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent Inc. and related stocks with our FREE daily email newsletter.